Diabetes Mellitus is Not a Risk Factor for Patients Supported with Left Ventricular Assist Device.
Diabetes mellitus (DM) has been proved to be a potent, independent risk factor for mortality in patients with heart failure. However, the influence of DM on post continuous-flow left ventricular assist device (CF-LVAD) implantation outcomes is still under debate. This study sought to investigate the effect of preoperative DM on all-cause mortality and major postoperative complications in patients with contemporary CF-LVAD support. A systematic literature search (PubMed, Embase, and ISI Web of Knowledge, and Cochrane Central Register of Controlled Trials) was performed. Primary endpoint was hazard ratio (HR) for all-cause mortality. Secondary endpoints were postoperative complications, including infection, transient ischemia attack, intracranial hemorrhage, and pump thrombosis. A meta-analysis was conducted to generate pooled HR and 95% confidence interval (CI) for all-cause mortality and pooled odds ratios (ORs) and 95% CIs for postoperative complications. A total of 1120 patients (Diabetic patients: 478; Nondiabetic patients: 642) from 4 studies were included in this study. DM did not increase the risk for all-cause mortality among patients with CF-LVAD support (HR, 1.33; 95% CI, 0.88-2.02; P=0.18). Moreover, pooled analysis demonstrated no significant difference was found in diabetic and nondiabetic groups in terms of infection (OR, 1.18; 95% CI, 0.89-1.56; P=0.24), transient ischemia attack (OR, 1.30; 95% CI, 0.86-1.97; P=0.21), intracranial hemorrhage (OR, 1.86; 95% CI, 0.93-3.71; P=0.08), and pump thrombosis (OR, 1.01; 95% CI, 0.68-1.48; P=0.97). The results of this meta-analysis demonstrate that DM does not increase all-cause mortality or rates of major adverse events during contemporary CF-LVAD support.